Intensive cholesterol drug lowering: How to be sure about their safety;Terapêutica redutora intensiva do colesterol: A certeza da segurança

Revista Portuguesa de Cardiologia

Volumn 29, Issue 9, 2010, Pages 1405-1418

  Marques Da Silva, Pedro ^a  

^a EPE ^*  (Portugal)

Author keywords

Adverse effects; Hepatotoxicity; LDL cholesterol; Myotoxicity; Proteinuria; Safety; Sstatins

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSLIPIDEMIA; HEALTH CARE QUALITY; HUMAN; LIVER TOXICITY; MYOPATHY; PATIENT COMPLIANCE; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; DRUG-INDUCED LIVER INJURY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MUSCULAR DISEASES;

EID: 78751690418     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Steinberg D. An interpretive history of the cholesterol controversy: part II: the early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res 2005; 46: 179-90
2. Steinberg D. An interpretive history of the cholesterol controversy, part V: the discovery of the statins and the end of the controversy. J Lipid Res 2006; 47: 1339-51
3. McKenney JM. Pharmacological options for aggressive low-density lipoprotein cholesterol lowering: benefit versus risks. Am J Cardiol 2005; 96 [suppl]: 60E-66E
4. Marques da Silva P. 25 Perguntas em Dislipidemias (Parte I). Sociedade Portuguesa de Aterosclerose. Lisboa: Permaneyer, 2006
5. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80
6. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-65
7. Crouse III JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. The METEOR trial. JAMA 2007; 297: 1344-53
8. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Beider R, Joyal SV, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504 (Errata em: N Engl J Med 2006; 354 (7): 778)
9. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-16
10. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35 (Pubitemid 40471450)
11. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-45
12. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78 (Errata em: Lancet 2005; 366 (9494): 1358)
13. Armitage J. The safety of statins in clinical practice. Lancet 2007; published on line June 7, 2007; DOI: 10.10167S0140.6736(07)60716-8
14. Grundy SM, Cleeman JI, Merz NB, Brewer, Jr HB, Clark LT et al. Implications of recent clinical trials for the National Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39
15. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol 2007; 49: 1753-62
16. Bays H. Statin safety: an overview and assessment of the data - 2005. Am J Cardiol 2006; 97 [suppl]: 6C-26C
17. Kashani A, Philipd CO, Foody JM, Wang Y, Mangalmurti S, et al. Risks associated with statin therapy. A systematic overview of randomized clinical trials. Circulation 2006; 114: 2788-97
18. Jacobson TA. The safety of aggressive statin therapy: how much can low-density lipoprotein cholesterol be lowered? Mayo Clin Proc 2006; 81: 1225-31
19. Wiviott SD, Cannon CP. The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy. Curr Opin Lipidol 2006; 17: 626-30
20. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-related adverse events: a meta-analysis. Clin Ther 2006; 28: 26-35
21. Kiortsis DN, Filippatos TD, Mikhailidis DP, Elisaf MS, Liberopoulos EN. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2006, doi: 10.1016/j.atherosclerosis.2006.10.001
22. Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther 2007; 29: 253-60
23. McClure DL, Valuck RJ, Glanz M, Hokanson JE. Systematic review and meta-analysis of clinically relevant adverse events from HMG CoA reductase inhibitor trials worldwide from 1982 to present. Pharmacoepidemiol Drug Saf 2007; 16: 132-43
24. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on the risk of elevated liver enzymes, rhabdomyolysis, and cancer. Insights from large randomized statin trials. J Am Coll Cardiol 2007; 50: 409-18
25. Dale KM, White CM, Henyan NN, Kluger J, Coleman CI. Impact of statin dosing intensity on transaminase and creatine kinase. Am J Med 2007; 120: 706-12
26. Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vascular Health and Risk Management 2008; 4: 341-53
27. Escobar C, Echarri R, Barrios V. Relative safety profiles of high dose statin regimens. Vascular Health and Risk Management 2008; 4: 525-33
28. Alsheikh-Ali AA, Karas RH. The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: evidence from clinical trials. Curr Atheroscl Rep 2009; 11: 100-4
29. O' Keefe JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl. Lower is better and physiologically normal. J Am Coll Cardiol 2004; 43: 2142-6 (Pubitemid 38686815)
30. Sabharwal AK, Boord JB. Low-density lipoprotein reduction: is the risk worth the benefit? Curr Atheroscler Rep 2006; 8: 19-25
31. Marques da Silva P. O doente com dislipidemia: a importância particular da terapêutica intensiva. Carrageta MO, ed. Guia Prático para a Prevenção da Doença Aterotrombótica. Lisboa: Permanyer, in press.
32. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E; PROVE IT-TIMI 22 Investigators. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46: 1411-6 (Errata em: J Am Coll Cardiol 2006; 47 (2): 472)
33. Marques da Silva P. Temas Cardiológicos: Dislipidemias. Volume 5: Tratamento. Lisboa: Vale & Vale Editores, 2002 (acesso http://www.saude- cardio.net/index)
34. Tiwari A, Bansal V, Chugh A, Mookhtiar K. Satins and miotoxicity: a therapeutic limitation. Expert Opin Drug Saf 2006; 5: 651-66
35. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006; 97 [suppl]: 77C-81C
36. Bottorff MB. Statin safety and drug interactions: clinical implications. Am J Cardiol 2006; 97 [suppl]: 27C-31C
37. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-81
38. Antons KA, Williams CD, Baker SK, Philips PS. Clinical perspectives of statin-induced rhabdomyolysis. Am J Med 2006; 119: 400-9
39. Thompson PD, Clarkson PM, Rosenson RS. An assessment of statin safety by muscle experts. Am J Cardiol 2006; 97[suppl]: 69C-76C
40. Schmitz G, Langmann T. Pharmacogenomics of cholesterol-lowering therapy. Vascular Pharmacol 2006; 44: 75-89
41. Vaklavas C, Chatzizisis YS, Ziakas A, Zamboulis C, Giannoglou GD. Molecular basis of statin-associated myopathy. Atherosclerosis 2009; 202: 18-28
42. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97: 52C-60C
43. Garcia MJ, Reinoso RF, Navarro AS, Prous JR. Clinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 2003; 25: 457-81
44. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hidroxy-3-methylglutaril coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Therap 2006; 112: 71-105
45. Neuvonen PJ, Niemi M, Backman JT Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006; 80: 565-81
46. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharmaceutical Sci 2006; 27: 425-46
47. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet 2002; 41: 343-70
48. Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol 2006; 1: 5-20
49. Prueksaritanont T, Subramanian R, Fang X, Ma B, Qiu Y, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002; 30: 505-12
50. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002; 30: 1280-7
51. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Experim Ther 2002; 301: 1042-51
52. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 2003; 73: 538-44
53. Vidt DG. Statins and proteinuria. Curr Atheroscl Rep 2005; 7: 351-7
54. Agarwal R. Effects of statins on renal function. Am J Cardiol 2006; 97: 748-55
55. Tiwari A. An overview of statin-associated proteinuria. Drug Discovery Today 2006; 11: 458-64
56. Kasiske BL, Wanner C, O'Neill WC. An assessment of statin safety by nephrologists. Am J Cardiol 2006; 97[suppl]: 82C-85C
57. Pollock CA, Poronnik P. Albumin transport and processing by the proximal tubule: physiology and pathophysiology. Curr Opin Nephrol Hypertens 2007; 16: 359-64
58. LaRosa JC. Means and ends of statins and low-density lipoprotein cholesterol lowering (Editorial comment). J Am Coll Cardiol 2007; 50: 419-20)
59. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006; 295: 74-80
60. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, on behalf of the TNT Steering Committee and Investigators. Safety and efficacy of atorvastatin at very low LDL-C levels. A post hoc analysis of the TNT study. Circulation 2005; 112 Suppl II: 662-3